Blueprint Medicines Corp
NASDAQ:BPMC
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
68.37
120.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Blueprint Medicines Corp
Operating Income
Blueprint Medicines Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Blueprint Medicines Corp
NASDAQ:BPMC
|
Operating Income
-$276m
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
||
Abbvie Inc
NYSE:ABBV
|
Operating Income
$15.4B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
||
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$10.9B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-1%
|
||
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$6.2B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
||
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
40%
|
CAGR 10-Years
N/A
|
||
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$4.2B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
Blueprint Medicines Corp
Glance View
Blueprint Medicines Corp. is a precision therapy company. The company is headquartered in Cambridge, Massachusetts and currently employs 495 full-time employees. The company went IPO on 2015-04-30. The firm delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib) to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include BLU-263 (KIT), AYVAKIT (avapritinib) (PDGFRA), BLU-701 (EGFR), BLU-945 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2) and BLU-852 (MAP4K1). The company is developing and commercializing avapritinib for the treatment of advanced SM, and developing avapritinib for the treatment of non-advanced SM. The firm is developing BLU-263, an investigational, orally available KIT inhibitor, for the treatment of non-advanced SM and other mast cell disorders.
See Also
What is Blueprint Medicines Corp's Operating Income?
Operating Income
-276m
USD
Based on the financial report for Sep 30, 2024, Blueprint Medicines Corp's Operating Income amounts to -276m USD.
What is Blueprint Medicines Corp's Operating Income growth rate?
Operating Income CAGR 5Y
6%
Over the last year, the Operating Income growth was 48%. The average annual Operating Income growth rates for Blueprint Medicines Corp have been 12% over the past three years , 6% over the past five years .